Germline mutations in specific hot spot-
codons of the RET proto-oncogene are associated with
multiple endocrine neoplasia type 2 (
MEN 2). Clinical RET gene testing has been routine for the last 10 years in some countries. In Argentina, RET testing excluding
MEN 2B was always reported with a mutation at
codon 634, with one exception: we described a novel mutation T > C transition at
codon 630 (C630R), the family to which we extend the study in the present report. This family comprised 29 members in four generations including 6 individuals affected with
medullary thyroid cancer (MTC), positive for the C630R mutation and normal
adrenaline/
noradrenaline and ionized
calcium/
parathyroid hormone levels. Two asymptomatic mutation carriers aged 5 and 11 years underwent total
thyroidectomy. The histopathologic examination showed C-cell
hyperplasia and microcarcinoma foci, while preoperative basal calcitonins were normal for both. Our report emphasizes the importance of testing for non-hot spot RET mutations in apparently mutation negative
MEN 2 families. Furthermore, it would appear that C630R mirrors C634R in penetrance (100% in this family) and in early age of onset of MTC, although paradoxically, no
pheochromocytomas and
hyperparathyroidism have developed. In addition to recommending RET testing before 5 years of age; we also can postulate that
codon 630 may be the key point along the extracellular domain, important in the tissue-specific penetrance.